Drug intelligence / Profile preview

GCS001

Development stage: Preclinical
Lead developer: Glen Clova Scientific

Overview

GCS001 is a preclinical drug candidate being developed by Glen Clova Scientific for the treatment of senile pruritus. It is one of three initial drug candidates from the company, with others targeting atopic dermatitis and eczema/asthma. As of April 2024, GCS001 remains in preclinical development and specific details regarding its mechanism of action, molecular target, or modality have not been publicly disclosed[2][9].

Beyond the preview

Go deeper on GCS001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GCS001.

Explore the full profile